AI's Widening Impact on Drug Development

Recent data shows venture investment in AI-focused biopharma companies appears to be accelerating to top last year’s record. However, the wide variance in applications and algorithms has complicated the ability to map progress in drug development techniques. As leaders in this space now begin to point to molecules moving into development and early clinical results, the prioritization of tools for other biotechs to consider adopting becomes clearer. This session will examine where AI is already improving current drug discovery and development and explore investors’ readiness to accelerate the field.